LeonaBio (LONA) Research & Development (2019 - 2026)
LeonaBio (LONA) posted quarterly Research & Development of $11.3 million for Q1 2026, up 161.79% year-over-year from $4.3 million in Q1 2025, and up 67.79% quarter-over-quarter from $6.7 million in Q4 2025.
LeonaBio (LONA) Research & Development (2019 - 2026) Analysis & Trends
LeonaBio (LONA) has reported Research & Development for 8 consecutive years, with $11.3 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Research & Development rose 161.79% year-over-year to $11.3 million; the TTM figure through Mar 2026 stood at $24.5 million (down 54.49% YoY), while the FY2025 annual figure was $17.5 million, down 75.24% from the prior year.
- Research & Development improved to $11.3 million in Q1 2026 per LONA's latest filing, from $6.7 million in the prior quarter.
- Across five years, Research & Development topped out at $27.2 million in Q3 2023 and bottomed at $2.8 million in Q3 2025.
- Historically, Research & Development has averaged $15.0 million across 5 years, with a median of $15.2 million in 2022.
- Annual changes were most pronounced in 2025 — Research & Development tumbled 84.24% — and 2026, when it surged 161.79%.
- LeonaBio's Research & Development stood at $15.2 million in 2022, then surged by 55.42% to $23.7 million in 2023, then tumbled by 60.43% to $9.4 million in 2024, then declined by 28.37% to $6.7 million in 2025, then surged by 67.79% to $11.3 million in 2026.
- Business Quant data shows LONA's Research & Development at $11.3 million in Q1 2026, $6.7 million in Q4 2025, and $2.8 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 993.80 Mn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.63 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.37 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 651.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 612.28 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 413.13 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 210.03 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 97.90 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -588.31 Mn |
| 10 | LeonaBio | 182.69 Mn | 131.62 Mn | - | 12.70 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.26 Mn |
| Dec 31, 2025 | 6.71 Mn |
| Sep 30, 2025 | 2.83 Mn |
| Jun 30, 2025 | 3.66 Mn |
| Mar 31, 2025 | 4.30 Mn |
| Dec 31, 2024 | 9.37 Mn |
| Sep 30, 2024 | 17.92 Mn |
| Jun 30, 2024 | 22.15 Mn |
| Mar 31, 2024 | 21.24 Mn |
| Dec 31, 2023 | 23.68 Mn |
| Sep 30, 2023 | 27.20 Mn |
| Jun 30, 2023 | 21.62 Mn |
| Mar 31, 2023 | 21.29 Mn |
| Dec 31, 2022 | 15.24 Mn |
| Sep 30, 2022 | 16.97 Mn |
| Jun 30, 2022 | 14.80 Mn |
| Mar 31, 2022 | 14.46 Mn |
| Dec 31, 2021 | 12.62 Mn |
| Sep 30, 2021 | 10.71 Mn |
| Jun 30, 2021 | 12.02 Mn |